Johnson & Johnson Reports the Acquisition of Shockwave Medical to Strengthen its MedTech Cardiovascular Portfolio
Shots:
- Johnson & Johnson has signed a definitive agreement to acquire Shockwave Medical, the transaction of which is anticipated to conclude by the mid of 2024
- As per the agreement, Johnson & Johnson will acquire all the Shockwave’s outstanding shares for $335.00 per unit making it a total deal value of ~$13.1B
- Through the acquisition, the company will enhance the MedTech cardiovascular portfolio with its focus on two of the cardiovascular indications incl. coronary artery disease (CAD) and peripheral artery disease (PAD)
Ref: Johnson & Johnson | Image: Johnson & Johnson
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
